Renal effects of prostaglandins and cyclooxygenase-2 inhibitors

Electrolyte and Blood Pressure

Volumn 6, Issue 1, 2008, Pages 35-41

  Kim, Gheun Ho ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Kidney; Kidney concentrating ability; Prostaglandins; Sodium

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; AQUAPORIN 2; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RENIN; ROFECOXIB; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; VASOPRESSIN;

ALDOSTERONE RELEASE; BARTTER SYNDROME; BLOOD PRESSURE; BODY WATER; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEEDBACK SYSTEM; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION RATE; HENLE LOOP; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LEG EDEMA; NATRIURESIS; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHUMAN; POTASSIUM TRANSPORT; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM ABSORPTION; SODIUM BALANCE; SODIUM RETENTION; UPREGULATION; VASOCONSTRICTION; WATER ABSORPTION;

EID: 50849084471     PISSN: 17385997     EISSN: None     Source Type: Journal    
DOI: 10.5049/EBP.2008.6.1.35     Document Type: Review

References (50)

1. Smith WL: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181-191, 1992
2. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235, 1971
3. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD: Paracrine regulation of the renal microcirculation. Physiol Rev 76:425-536, 1996
4. Schlondorff D, Ardaillou R: Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int 29:108-119, 1986
5. Breyer MD, Jacobson HR, Breyer RM: Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 7:8-17, 1996
6. Breyer MD, Zhang Y, Guan YF, Hao CM, Hebert RL, Breyer RM: Regulation of renal function by prostaglandin E receptors. Kidney Int 54(Suppl 67):S88-94, 1998
7. Villa E, Garcia-Robles R, Haas J, Romero JC: Comparative effect of PGE2 and PGI2 on renal function. Hypertension 30:664-666, 1997
8. Shankar SS, Brater DC: Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 284:F11-21, 2003
9. Fernandez-Llama P, Ecelbarger CA, Ware JA, Andrews P, Lee AJ, Turner R, et al.: Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop. Am J Physiol 277:F219-226, 1999
10. Whelton A, Hamilton CW: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 31: 588-598, 1991
11. Carmichael J, Shankel SW: Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 78:992-1000, 1985
12. Romero JC, Bentley MD, Vanhoutte PM, Knox FG: Intrarenal mechanisms that regulate sodium excretion in relationship to changes in blood pressure. Mayo Clin Proc 64:1406-1424, 1989
13. Arima S, Ren Y, Juncos LA, Carretero OA, Ito S: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 45:650-658, 1994
14. Welch WJ, Wilcox CS: Modulating role for thromboxane in the tubuloglomerular feedback response in the rat. J Clin Invest 81:1843-1849, 1988
15. Brady HR, Papayianni A, Serhan CN: Leukocyte adhesion promotes biosynthesis of lipoxygenase products by transcellular routes. Kidney Int 45(Suppl 45):S90-97, 1994
16. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510, 1994
17. Welch WJ, Wilcox CS, Dunbar KR: Modulation of renin by thromboxane: studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic. Am J Physiol 257:F554-560, 1989
18. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 272:F460-468, 1997
19. Guan Y, Chang M, Cho W, Zhang Y, Redha R, Davis L, et al.: Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 273:F18-26, 1997
20. Khan KN, Stanfield KM, Harris RK, Baron DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 23:321-330, 2001
21. Adegboyega PA, Ololade O: Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 12:71-74, 2004
22. Ferguson S, Hebert RL, Laneuville O: NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol 10:2261-2271, 1999
23. Luft FC, Wilcox CS, Unger T, Kuhn R, Demmert G, Rohmeiss P, et al.: Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 14:396-403, 1989
24. Moeckel GW, Zhang L, Fogo AB, Hao CM, Pozzi A, Breyer MD: COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress. J Biol Chem 278:19352-19357, 2003
25. Kwon TH: Dysregulation of renal cyclooxygenase-2 in rats with lithium-induced nephrogenic diabetes insipidus. Electrolyte Blood Press 5:68-74, 2007
26. Harris RC: The macula densa: recent developments. J Hypertens 14:815-822, 1996
27. Hartner A, Goppelt-Struebe M, Hilgers KF: Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 31:201-205, 1998
28. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, et al.: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 103:953-961, 1999
29. Yang T, Singh I, Pham H, Sun D, Smart A, Schnermann JB, et al.: Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 274:F481-489, 1998
30. Zewde T, Mattson DL: Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44:424-428, 2004
31. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 56:383-388, 2000
32. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255, 2000
33. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735-741, 1999
34. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72:50-61, 2002
35. Whelton A: COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens 20(Suppl6): S31-35, 2002
36. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121:289-300, 1994
37. Hocherl K, Endemann D, Kammerl MC, Grobecker HF, Kurtz A: Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 136:1117-1126, 2002
38. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, et al.: Opposite effects of cyclooxygenase-1 and -2 activity on-the pressor response to angiotensin II. J Clin Invest 110:61-69, 2002
39. Harris RC, Zhang MZ, Cheng HF: Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand 181:543-547, 2004
40. Castrop H, Schweda F, Schumacher K, Wolf K, Kurtz A: Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 12:867-874, 2001
41. Yang T, Park JM, Arend L, Huang Y, Topaloglu R, Pasumarthy A, et al.: Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem 275:37922-37929, 2000
42. Kammerl MC, Nusing RM, Seyberth HW, Riegger GA, Kurtz A, Kramer BK: Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch 442:842-847, 2001
43. Reinalter SC, Jeck N, Brochhausen C, Watzer B, Nusing RM, Seyberth HW, et al.: Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/ antenatal Bartter syndrome. Kidney Int 62:253-260, 2002
44. Dunn MJ: Prostaglandin I2 and the kidney. Arch Mal Coeur Vaiss 82 Spec No 4:27-31, 1989
45. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M: Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76-84, 1999
46. Perazella MA, Tray K: Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 111:64-67, 2001
47. Vaisbich MH, Fujimura MD, Koch VH: Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858-863, 2004
48. Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M: Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 149:1123-1126, 1989
49. Soylu A, Kasap B, Ogun N, Ozturk Y, Turkmen M, Hoefsloot L, et al.: Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. Pediatr Nephrol 20:1814-1817, 2005
50. Kim GH, Choi NW, Jung JY, Song JH, Lee CH, Kang CM, et al.: Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2. Am J Physiol Renal Physiol 294:F702-709, 2008